Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Mereo BioPharma Group plc - Sponsored ADR (MREO) had Return on Tangible Equity of -71.70% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-43.25M |
|
-- |
|
-- |
|
$47.36M |
|
$-47.36M |
|
$4.11M |
|
$-43.25M |
|
$-43.25M |
|
$-43.25M |
|
$-43.25M |
|
$-43.25M |
|
$-43.25M |
|
$-47.36M |
|
$-46.78M |
|
147.93M |
|
147.93M |
|
$-0.29 |
|
$-0.29 |
|
| Balance Sheet Financials | |
$74.76M |
|
$0.26M |
|
$1.63M |
|
$76.39M |
|
$13.85M |
|
-- |
|
$1.57M |
|
$15.42M |
|
$60.97M |
|
$60.33M |
|
$60.97M |
|
155.15M |
|
| Cash Flow Statement Financials | |
$-32.83M |
|
$-0.70M |
|
$46.15M |
|
$57.42M |
|
$69.80M |
|
$12.38M |
|
$7.39M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.40 |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-32.83M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-70.94% |
|
|
Return on Tangible Equity |
-71.70% |
-56.62% |
|
-70.94% |
|
$0.39 |
|
$-0.22 |
|
$-0.22 |
|